Inventiva S.A.

NASDAQ:IVA

Biotechnology

Healthcare
$3.39 +0.42%

+$0.02 today

Market cap
$176.22M
Beta
0.88
P/E (TTM)
-5.5
EPS (TTM)
-$0.56
52W Low $2.85High $7.98

Volume 3.54M

Average 0.45M

IVA Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Inventiva S.A.NASDAQ: IVA

Accounts Receivables · Q4 FY2025 · quarter ended Dec 2025

Accounts receivables grows 247.3% year over year

Q4 FY2025 accounts receivables of €9.75M rose 247.3% year over year. Over 3 fiscal years it compounded at -40.3% a year.

Context

  • Accounts receivables amounted to 18.2% of revenue in FY2025, down 12.3 pp from a year earlier.
  • Accounts receivables increased in 1 of the last 3 fiscal years.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterDec 2025
€9.75M— QoQ
Last fiscal yearDec 2025
€816.45K-70.9% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+247.3%——
1 year-70.9%——
3-year CAGR-40.3%——
5-year CAGR——
10-year CAGR——

Accounts Receivables history

EUR · from the cash flow

Latest · FY2025
816.45K EUR
Year-over-year change
-70.9%

Accounts Receivables vs competitors

How IVA compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -70.9% is the lowest of 8, against a peer median of +100.0%.
  • Accounts receivables amounts to 18.2% of revenue for IVA, versus a peer median of 6.2%.
IVA Competitors
Accounts Receivables for IVA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$32.8M USD+4000.1%+39.1%47.4%
TNYATenaya Therapeutics, Inc.LTM Mar 2026$10.63M USD——4723.1%
IVVDInvivyd, Inc.LTM Mar 2026$3.46M USD-39.0%—6.2%
RNACCartesian Therapeutics, Inc.LTM Mar 2026$1.5M USD-42.4%—84.7%
IVAInventiva S.A.FY2025€816.45K EUR-70.9%-40.3%18.2%
EPRXEupraxia Pharmaceuticals Inc.LTM Mar 2026$405.95K USD+181.5%——
CRBUCaribou Biosciences, Inc.LTM Mar 2026$378K USD-56.7%-57.2%3.4%
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$5K USD+171.4%—0.0%
AVTXAvalo Therapeutics, Inc.LTM Mar 2026$0 USD+100.0%—0.0%
NAUTNautilus Biotechnology, Inc.LTM Mar 2026$0 USD———
Peer median (excluding IVA) —+100.0%-9.0%6.2%

Competitors are the stored peer set for IVA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(49.64M)(54.27M)(110.43M)(184.21M)(340.16M)
Depreciation & Amortization(1.29M)1.7M2.6M5.2M3.22M
Deferred Income Tax(3.27M)(5.26M)(4.74M)(4.8M)(2.3M)
Stock-Based Compensation2.09M2.22M3.97M3.58M26.77M
Change in Working Capital979K5.71M17.31M1.68M6.42M
Accounts Receivables(5.32M)3.84M(5.84M)2.81M816.45K
Inventory(72K)19K(44K)417K0
Accounts Payables7.6M3.54M20M02.46M
Other Working Capital(1.23M)(1.69M)3.19M(1.54M)3.15M
Other Non-Cash Items3.5M4.98M9.68M92.63M205.07M
Operating Cash Flow(47.63M)(44.93M)(81.61M)(85.93M)(100.98M)
Capital Expenditures(534K)(561K)(540K)(333K)(237.26K)
Acquisitions (Net)89K41K000
Purchases of Investments(1.35M)(1K)(8.3M)0(127.69M)
Sales of Investments(89K)9.39M978K9.08M0
Other Investing Activities90K1K131K75.72K(1K)
Investing Cash Flow(1.79M)8.87M(7.73M)8.75M(127.93M)
Debt Repayment(28K)28.44M(4.1M)19.92M(5.98M)
Common Stock Issued25.48M8.83M28.08M57.34M237.74M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(17.73K)(772.47K)5.1M68.33M236.98K
Financing Cash Flow25.45M37.27M29.08M145.59M232M
Effect of Forex Changes4.84M(1.03M)445K1.24M11.08M
Net Change in Cash(19.13M)183K(59.82M)69.65M14.17M
Free Cash Flow(48.16M)(45.49M)(82.15M)(86.26M)(101.22M)

Inventiva S.A.

NASDAQ:IVA

Intrinsic Alpha fair value

Locked

Current Price

$3.39

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.